Novel agent may be new standard, ‘launching point’ in chondrosarcoma (opens in new tab)

CHICAGO — A novel tetravalent DR5 agonist could become the first standard of care for conventional chondrosarcoma.Updated data from the first positive randomized trial in this disease showed ozekibart (INBRX-109, Inhibrx Biosciences Inc.) doubled median PFS and improved multiple other efficacy outcomes compared with placebo.The magnitude of benefit — though modest by typical oncology standards — exceeds what has been achieved with other agents in this setting.“There are no FDA-approved therap...